首页> 外文OA文献 >Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

【2h】

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

机译：利妥昔单抗维持可改善有或无利妥昔单抗的患者在诱导期间复发/耐药的滤泡性非霍奇金淋巴瘤的临床结果：一项前瞻性随机3期组间试验的结果

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
van Oers Marinus H. J.; Klasa Richard; Marcus Robert E.; Wolf Max; Kimby Eva; Gascoyne Randy D.; Jack Andrew; vant Veer Mars; Vranovsky Andrej; Holte Harald; van Glabbeke Martine; Teodorovic Ivana; Rozewicz Cynthia; Hagenbeek Anton;
展开▼
作者单位

展开▼
年度 2006
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. [J] . van Oers MH, Van Glabbeke M, Giurgea L, Journal of Clinical Oncology . 2010,第17期

机译：利妥昔单抗维持治疗复发/耐药的滤泡性非霍奇金淋巴瘤：EORTC 20981 III期随机分组研究的长期结果。
2. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-na?ve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial [J] . Pier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, Journal of Hematology and Oncology . 2012,第6期

机译：硼替佐米联合利妥昔单抗与利妥昔单抗治疗高危，复发，利妥昔单抗初治或利妥昔单抗敏感的滤泡性淋巴瘤的患者：一项随机3期试验的亚组分析
3. Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. [J] . Ruth Pettengell, Norbert Schmitz, Christian Gisselbrecht, Journal of Clinical Oncology . 2013,第13期

机译：Rituximab吹入和/或维持在接受复发卵泡淋巴瘤的自体移植中：来自欧洲血液和骨髓移植的淋巴瘤工作组的前瞻性随机试验。
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkins Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study [O] . Marinus H.J. van Oers, Martine Van Glabbeke, Livia Giurgea, -1

机译：利妥昔单抗维持治疗复发/耐药的滤泡性非霍奇金淋巴瘤：EORTC 20981 III期随机分组研究的长期结果
6. Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study [O] . van Oers, Marinus H.J., Van Glabbeke, Martine, Giurgea, Livia, 2010

机译：利妥昔单抗维持治疗复发/耐药滤泡性非霍奇金淋巴瘤：EORTC 20981 III期随机分组研究的长期结果

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

著录项

引文网络

相似文献

相关主题

期刊订阅